Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma

Inclusion Criteria: * Histologically confirmed adenocarcinoma of the pancreas that is surgically inoperable * Must have had one prior chemotherapeutic regimen for advanced disease (Prior radiation with a radiation sensitizer for locally advanced disease or adjuvant therapy is not considered a prior regimen for purpose of this study) * Disease must be measurable by RECIST criteria; measurable disease will be defined as at least one lesion that can be accurately measured in at least one dimension measuring at least 2 cm conventional CT or MRI or 1 cm with spiral CT scans (Appendix A) * Aged 18 years or older * ECOG performance status of 0 - 2 (see Appendix B) * Able to take oral medications without difficulty * Adequate bone marrow function as evidenced by an ANC \> 1500/mL and platelet count \> 100, 000/mL * Adequate renal function as evidenced by serum creatinine within institutional limits or creatinine clearance \> 60 ml/minute if above upper institutional limits (ULN) * Adequate hepatic function as evidenced by ALT, AST, and total bilirubin within ULN. If hepatic metastases are present, ALT and AST may be up to 5 x ULN. * Provision of written informed consent * Men and women of childbearing potential must be willing to practice acceptable methods of birth control to prevent pregnancy. This is a precautionary measure for use of Gefitinib and docetaxel. Exclusion Criteria: * Known severe hypersensitivity to Gefitinib or docetaxel or any of the excipients of these products (i.e. polysorbate 80) * Previous treatment with Gefitinib or docetaxel. * Other coexisting malignancies or malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma or squamous cell carcinoma of the skin or cervical cancer in situ. * Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital, or St John's Wort * Treatment with a non-approved or investigational drug within 30 days before Day 1 of trial treatment. * Treatment with radiation therapy or chemotherapy within 28 days before Day 1 of trial treatment * Any unresolved chronic toxicity greater then CTC grade 2 from previous anticancer therapy (except alopecia) * Incomplete healing from previous oncologic or other major surgery. * Pregnancy or breast feeding (women of childbearing potential). * Any evidence of clinically active interstitial lung disease (patients with chronic stable radiographic changes who are asymptomatic need not be excluded). * As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease). * Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the trial.